CONTACT US   |  (864) 397-5101

Nephron To Produce 0.5% Albuterol 5 mL, Alleviating Nationwide Shortage

Nephron

Nephron Pharmaceuticals Corporation today announced that preservative-free 0.5% Albuterol Sulfate Inhalation Solution is available now in a 25 mg/5 mL pre-filled vial.

Nephron received FDA approval for Albuterol 0.5% 0.5 mL in 2001 and now provides millions of doses per year to patients nationwide.

0.5% Albuterol Sulfate Inhalation Solution 25 mg/5 mL
0.5% Albuterol Sulfate Inhalation Solution 25 mg/5 mL

In addition to Albuterol 0.5% 0.5 mL produced by Nephron, Nephron 503B Outsourcing Facility is now offering a larger fill volume of this essential product directly to hospitals and medical facilities, in an effort to alleviate the nationwide shortage.

“Patients, families and healthcare providers should never worry about access to life-saving medication, and here at Nephron, making sure they have what they need is precisely what keeps us motivated,” said Lou Kennedy, CEO and Owner of Nephron. “As we continue to keep the needs of patients and families a top priority, they can count on us – and that makes us proud.”

The 5 mL concentrated vial is available for use with continuous nebulization for adults and pediatric patients. This new, easy-to-dispense fill volume will save respiratory therapists valuable time and resources during patient care.

To place an order, customers can contact Nephron directly at NOFaccounts@nephronpharm.com or 1-844-224-2225.

A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. For more information, please visit www.nephronpharm.com.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.